Fresenius (FRE) Stock Price, Fundamentals & Analysis

What FRE does

Fresenius (FRE) is a health care company that provides products and services for chronically ill patients across North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through two main segments: Fresenius Kabi, which supplies biopharmaceuticals, clinical nutrition, IV fluids, MedTech products, and biosimilar drugs; and Fresenius Helios, which runs hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, along with medical diagnostics. The company is collaborating with SAP SE and Avelios Medical GmbH on a cloud-native, modular hospital information system that integrates AI into clinical and administrative processes. Fresenius is listed on the Xetra stocks segment and is part of the broader German healthcare ecosystem that includes peers such as Siemens Healthineers (SHL), Fresenius Medical Care (FME), and Merck (MRK).

Key numbers explained

• 46,15 EUR is the current share price on the Xetra exchange.
• The trailing P/E ratio of 16,7 shows how much investors pay per euro of the company's last 12 months' earnings; a lower figure can suggest a more attractive valuation relative to earnings.
• The forward P/E ratio of 11,7 uses expected future earnings and is often read as a gauge of how the market views the company's growth prospects.
• 2,77 EUR is the trailing 12-month earnings per share, representing the portion of profit allocated to each share.
• The dividend yield of 2,28% indicates the annual dividend payment as a percentage of the current share price.
• 38% is the share of earnings paid out as dividends, showing how much of the company's profit is returned to shareholders.
• Beta of 0,84 suggests the stock has historically been less volatile than the overall market.
• 25,99 mld. EUR is the market capitalization, the total market value of all outstanding shares.

What to watch

• Revenue growth of 5,2% year over year and a profit margin of 6,5% provide a sense of the company's top-line expansion and cost control.
• The operating margin of 10,6% and return on equity of 8,3% help assess how efficiently the company turns sales and shareholder capital into profit.
• The debt-to-equity ratio of 56% is a measure of financial leverage that investors often compare across peers in the sector.
• The 52-week price range of 35,11 – 52,96 EUR and the one-year price change of -1,6% show recent price volatility and trend.
• The next earnings release is scheduled for 4 nov. 2026, and the ex-dividend date is 25 mai 2026, both of which are key dates for income-focused and earnings-driven investors.